Alnylam Pharmaceuticals (ALNY) vs BioMarin Pharmaceutical (BMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioMarin Pharmaceutical (BMRN) has outperformed Alnylam Pharmaceuticals (ALNY) over the past year, gaining 10.5% versus a loss of 67.0%. Over five years, ALNY leads with a -23.7% price change compared with -31.0% for BMRN. Alnylam Pharmaceuticals is the larger company by market cap ($19.26 billion vs $11.70 billion), about 1.6 times the size.
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (9.6x vs 14.5x for Alnylam Pharmaceuticals). BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus 8.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALNY | BMRN |
|---|---|---|
| Share price | $143.82 | $60.41 |
| Market cap | $19.26B | $11.70B |
| 1-day change | -2.71% | -1.64% |
| YTD return | -63.83% | +1.65% |
| 1-year return | -67.04% | +10.46% |
| 5-year return | -23.72% | -31.02% |
| P/E ratio (TTM) | 7.26 | — |
| Forward P/E | 14.51 | 9.60 |
| EPS (TTM) | $19.80 | $-0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.71B | $3.22B |
| Revenue growth (YoY) | +65.19% | +12.87% |
| Net income (latest FY) | $313.75M | $348.90M |
| Gross margin | 81.77% | 77.73% |
| Operating margin | 13.51% | 12.71% |
| Net margin | 8.45% | 10.83% |
| 52-week high | $479.79 | $70.98 |
| 52-week low | $143.40 | $49.26 |
| Distance from 52-week high | -70.02% | -14.89% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +101.10% | +49.48% |
| Average volume | 2.09M | 2.35M |
| Shares outstanding | 133.94M | 193.69M |
| Employees | 2,500 | 3,221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMRN has outperformed ALNY by 77.5 percentage points over the past year.
- Alnylam Pharmaceuticals grew revenue faster in its latest fiscal year (+65.19% vs +12.87%).
About Alnylam Pharmaceuticals
ALNY stock →Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,500 employees
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
ALNY vs BMRN FAQ
Which is bigger, Alnylam Pharmaceuticals or BioMarin Pharmaceutical?
Alnylam Pharmaceuticals (ALNY) is larger, with a market capitalization of $19.26B compared with $11.70B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, ALNY or BMRN?
BMRN returned +10.46% over the past 12 months, compared with -67.04% for ALNY (price return, excluding dividends). Past performance does not predict future results.
Are Alnylam Pharmaceuticals and BioMarin Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.